{"id":"zkab001","safety":{"commonSideEffects":[{"rate":null,"effect":"Unknown"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"ZKAB001 works by binding to the molecular target, which results in the desired therapeutic effect.","oneSentence":"ZKAB001 is a small molecule drug that targets the molecular target.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:41:27.216Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Unknown"}]},"trialDetails":[{"nctId":"NCT04878016","phase":"PHASE3","title":"A Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-PD-L1 Antibody) in Patients With ES-SCLC","status":"COMPLETED","sponsor":"Lee's Pharmaceutical Limited","startDate":"2021-07-15","conditions":"Extensive-stage Small-cell Lung Cancer","enrollment":498},{"nctId":"NCT04346914","phase":"PHASE1","title":"Study of ZKAB001 Combined With Carboplatin and Etoposide in the Extensive Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Lee's Pharmaceutical Limited","startDate":"2020-03-08","conditions":"Extensive Stage Small Cell Lung Cancer","enrollment":20},{"nctId":"NCT04460066","phase":"PHASE1, PHASE2","title":"A Study of Anti-PD-L1 Antibody in Neoadjuvant Chemotherapy of Esophageal Squamous Cell Carcinoma.","status":"UNKNOWN","sponsor":"Lee's Pharmaceutical Limited","startDate":"2020-11-18","conditions":"Esophageal Cancer","enrollment":70},{"nctId":"NCT04849260","phase":"PHASE1, PHASE2","title":"Phase Ib/II Clinical Study of Pexa-Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Combined With Recombinant Whole Human Anti-PD-L1 Monoclonal Antibody (ZKAB001) in Metastatic Melanoma","status":"UNKNOWN","sponsor":"Lee's Pharmaceutical Limited","startDate":"2021-08-26","conditions":"Local Progression or Metastatic Melanoma With Failed First-line Treatment","enrollment":54},{"nctId":"NCT04603846","phase":"PHASE1","title":"A Study of Anti-PD-L1 Antibody ZKAB001 Combined With Albumin-bound Paclitaxel in Advanced Urothelial Carcinoma","status":"UNKNOWN","sponsor":"Lee's Pharmaceutical Limited","startDate":"2020-09-10","conditions":"Advanced Urothelial Carcinoma","enrollment":20},{"nctId":"NCT04608786","phase":"PHASE1","title":"A Clinical Study of PD-L1 Antibody ZKAB001 Combined With Capecitabine in Resected Biliary Tract Cancer","status":"UNKNOWN","sponsor":"Lee's Pharmaceutical Limited","startDate":"2021-02-01","conditions":"Biliary Tract Cancer","enrollment":10},{"nctId":"NCT03676959","phase":"PHASE1","title":"A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Recurrent or Metastatic Cervical Cancer","status":"UNKNOWN","sponsor":"Lee's Pharmaceutical Limited","startDate":"2018-08-16","conditions":"Cervical Cancer","enrollment":101},{"nctId":"NCT04359550","phase":"PHASE3","title":"Study of ZKAB001 for Maintenance Therapy in Patients With High-grade Osteosarcoma After Adjuvant Chemotherapy","status":"UNKNOWN","sponsor":"Lee's Pharmaceutical Limited","startDate":"2020-06-01","conditions":"High-grade Osteosarcoma","enrollment":362},{"nctId":"NCT03676985","phase":"PHASE1, PHASE2","title":"A Clinical Study of PD-L1 Antibody ZKAB001(Drug Code) in Limited Stage of High-grade Osteosarcoma","status":"UNKNOWN","sponsor":"Lee's Pharmaceutical Limited","startDate":"2018-10-10","conditions":"Osteosarcoma","enrollment":15},{"nctId":"NCT03676946","phase":"PHASE1, PHASE2","title":"A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Locally Advanced and Metastatic Urothelial Carcinoma","status":"UNKNOWN","sponsor":"Lee's Pharmaceutical Limited","startDate":"2018-10-10","conditions":"Urothelial Carcinoma","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ZKAB001","genericName":"ZKAB001","companyName":"Lee's Pharmaceutical Limited","companyId":"lee-s-pharmaceutical-limited","modality":"Biologic","firstApprovalDate":"","aiSummary":"ZKAB001 is a small molecule drug that targets the molecular target. Used for Unknown.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}